Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Pre-Tax Margin

The Pre-Tax Profit Margin of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 13, 2026 is 11.99 %. In the previous year, Pre-Tax Profit Margin was 8.57 % — a change of 39.83% (higher).

Pre-Tax Margin

11.99 %

YoY

39.83%

Last updated:

Pre-Tax Profit Margin of Vcanbio Cell & Gene Engineering Corp is 2025 11.99 % . Pre-Tax Profit Margin of Vcanbio Cell & Gene Engineering Corp was 2024 8.57 % . It decreases by 39.83% higher compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
7.92 CNY
Jan 1, 2019
8.18 CNY
Jan 1, 2020
-6.76 CNY
Jan 1, 2021
14.52 CNY
Jan 1, 2022
9.98 CNY
Jan 1, 2023
8.34 CNY
Jan 1, 2024
8.57 CNY
Jan 1, 2025
11.99 CNY
The Vcanbio Cell & Gene Engineering Corp Pre-Tax Margin history
YEARPre-Tax MarginYoY
11.99 %+39.83%
8.57 %+2.81%
8.34 %-16.45%
9.98 %-31.26%
14.52 %-314.97%
-6.76 %-182.55%
8.18 %+3.35%
7.92 %+68.06%
4.71 %-57.57%
11.10 %-69.98%
36.99 %+179.42%
13.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Pre-Tax Profit Margin of Vcanbio Cell & Gene Engineering Corp is 11.99 % in 2025.

Pre-Tax Profit Margin of Vcanbio Cell & Gene Engineering Corp changed from 8.57 % to 11.99 %, representing a 39.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Vcanbio Cell & Gene Engineering Corp

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Vcanbio Cell & Gene Engineering Corp